Liquid Biopsy Shows which Post-Treatment Bladder Cancer Patients Won’t Relapse
June 18, 2024 | Terry Sharrer
“Results of the IMvigor011 Phase III trial show that more than 90 percent of muscle invasive bladder cancer patients with a negative circulating tumor DNA (ctDNA) test following surgery, that remained negative at follow up, did not relapse. The results of the trial, presented today at the European Association of Urology Congress in Paris, indicate that using a liquid biopsy ctDNA test could allow some patients to be spared additional treatment, with limited risk.” MORE
Image Credit: InsidePrecisionMedicine